Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New app aims to empower hepatitis delta patients in their own care

NCT ID NCT07442760

Knowledge-focused Sponsor: FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a mobile app called ePro-Diary HDV for people with hepatitis Delta, a rare but serious liver disease. The app helps patients track their health, communicate with doctors, and remember appointments. Researchers want to see if using the app helps patients attend more follow-up visits and improves their quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mobile application (ePro-Diary HDV)
What this could lead to
If successful, this app could help patients with hepatitis Delta stay on track with their care and improve communication with their doctors.
What could go wrong
This is a small, early study testing a digital tool, not a new drug. The app may not work for everyone or may not improve health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 55 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Mar 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with chronic HDV hepatitis attending the Hepatology Clinics of ASST Papa Giovanni XXIII who meet the inclusion criteria will be included. For enrolled patients given access to the app, retrospective data collection will also be performed from the time of Delta's hepatitis diagnosis.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 years * Diagnosis of Delta infection (anti-HDV positivity) * Signed informed consent * Ability to adequately understand instructions for correctly using mobile device applications. Exclusion Criteria: * Refusal or inability to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HDV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatitis hepatitis D virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HDV HDV infection Hepatitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ASST-Papa Giovanni XXIII

    RECRUITING

    Bergamo, Italy, 24127, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.